Strategic Advisors
|
Deborah Ancona, PhD Seley Distinguished Professor of Management; Professor of Organization Studies; Faculty Director, MIT Leadership Center, MIT Sloan School of Management |
Retsef Levi, PhD J. Spencer Standish (1945) Professor of Management; Associate Professor of Operations Management, MIT Sloan School of Management |
|
Denny A. Ausiello, MD CATCH Co-Founder, Director; Jackson Professor of Clinical Medicine, Harvard Medical School; Chief of Medicine, MGH; Director, Pfizer |
Andrew Lo, PhD Charles E. and Susan T. Harris Professor of Finance; Director, Laboratory for Financial Engineering, MIT Sloan School of Management |
|
Ernest Berndt, PhD, MS Louis E Seley Professor of Applied Economics, Sloan School of Management; Co-director Biomedical Enterprise Program |
Ram Sasisekharan, PhD Director, Harvard – MIT Health Sciences and Technology, Edward Hood Taplin Professor of Health Sciences & Technology and Biological Engineering, MIT |
|
Charles L. Cooney, PhD Robert T. Haslam Professor of Chemical Engineering, MIT; Faculty Director, Deshpande Center for Technological Innovation |
Phillip A. Sharp, PhD Institute Professor, Koch Institute for Integrative Cancer Research, MIT |
|
Michael A. Cusumano, PhD Sloan Management Review Distinguished Professor of Management, MIT Sloan School of Management |
Anthony Sinskey, ScD Faculty Director, CBI; Professor of Biology and Health Sciences and Technology, MIT |
|
Elazer Edelman, MD, PhD, FACC Thomas D & Virginia W Cabot Professor of HST, Health Sciences and Technology Program, MIT |
Executive Committee
The Executive Committee for NEWDIGS is an advisory body, which meets once a quarter throughout the calendar year. The role of the Executive Committee is to contribute ideas for projects, vet new opportunities, and disseminate emerging insights and recommendations from NEWDIGS activities The Executive Committee will assist with outreach to potential sponsors and endorse the goals of NEWDIGS projects as well the alignment of new projects with NEWDIGS mission and priorities; It has no financial or fiduciary responsibility, nor does it make any product-specific decisions. Typical agenda items include research updates, workshop opportunities, new mini-consortia proposals and pending publications.
|
Elizabeth Cobbs, PhD Head, Medical Policy & Quality Research Merck & Co. Inc. |
Kenneth A. Oye, PhD Associate Professor of Political Science and Engineering Systems;; Co-Director, MIT Program on Emerging Technologies Massachusetts Institute of Technology |
|
Nick Crabb, PhD Program Director, Scientific Affairs National Institute for Health & Clinical Excellence (NICE) |
Edmund J. Pezalla, MD, MPH Scholar in Residence Duke-Robert J. Margolis Center for Health Policy at Duke University |
|
Anne-Virginie Eggimann, MSc Vice President, Regulatory Science bluebird bio |
Peter Saltonsall President and CEO National Organization for Rare Disorders (NORD) |
|
Hans-Georg Eichler, MD, MSc Senior Medical Officer European Medicines Agency |
Harry Selker, MD, MSPH Dean, Clinical and Translational Science Institute Institute for Clinical Research & Health Policy Studies Tufts University |
|
Gigi Hirsch, M.D. Executive Director MIT Center for Biomedical Innovation Massachusetts Institute of Technology |
Mark Trusheim, MSc Strategic Director, NEWDIGS; Visiting Scientist, Sloan School of Managment Massachusetts Institute of Technologye; President, Co-Bio Consulting |
|
Hilary M. Malone, PhD Chief Regulatory Officer, Head of Global Regulatory Affairs Sanofi |
Affiliated Faculty and Researchers
|
Allison Ackerman Shrier, MD President, Riptide Management |
Kenneth A. Oye, PhD Associate Professor of Political Science and Engineering Systems;; Co-Director, MIT Program on Emerging Technologies Massachusetts Institute of Technology |
|
Ramy Arnaout, MD, DPhil Associate Director, Department of Pathology, Beth Israel Deaconess Medical Center |
Nitin R. Patel, PhD Research Affiliate, MIT Center for Biomedical Innovation; Founder, Chairman, and Chief Technology Officer, Cytel Statistical Software and Services |
|
Ernest Berndt, PhD, MS Louis E Seley Professor of Applied Economics, Sloan School of Management; Co-director Biomedical Enterprise Program |
G.K. Raju, PhD CBI Distinguished Fellow; Chairman, CBI Biomanufacturing Steering Committee; Executive Director, MIT Pharmaceutical Manufacturing Initiative |
|
Jeff Brown, PhD Assistant Professor, Department of Population Medicine, Harvard Medical School |
J. Russell Teagarden, DMH, MA Senior Health Care Practitioner, Independent Advisor, Researcher and Writer |
|
Chester Drum, MD, PhD Assistant Professor, Department of Medicine, National University of Singapore |
Mark Trusheim, MSc Strategic Director, NEWDIGS; Visiting Scientist, Sloan School of Managment Massachusetts Institute of Technologye; President, Co-Bio Consulting |
|
Judy Maro, PhD, MS Research Affiliate, Center for Biomedical Innovation, Research Fellow in the Department of Population Medicine at Harvard Medical School and the Harvard Pilgrim Health Care Institute |
Program Leadership Office
|
Gigi Hirsch, M.D. ghirsch@mit.edu Executive Director MIT Center for Biomedical Innovation Massachusetts Institute of Technology 617-253-9609 |
Katie Torrence ktorrenc@mit.edu Project Coordinator, Financing and Reimbursement of Cures in the US (FoCUS) 617-324-2695 |
|
Kay Larholt, ScD klarholt@mit.edu Director of Integrated Knowledge Solutions, WISDOM Program 617-253-7333 |
Mo Yang, PhD Health Economics and Financing Research Lead, Financing and Reimbursement of Cures in the US (FoCUS) Program 617-324-2695 |
|
Eric A. Small easmall@mit.edu Administrative Coordinator, NEWDIGS 617-324-4841 |
Deborah L. Young, EMBA, Ed.M. debyoung@mit.edu Director of Operations 617-324-7756 |
|
Magdi Stino, PhD stino@mit.edu Postdoctoral Associate, Financing and Reimbursement of Cures in the US (FoCUS) 617-324-7261 |
